NCT06473259View on ClinicalTrials.gov

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

RecruitingOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

December 16, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Prostate CancerHormone Sensitive Prostate CancerMetastatic Tumor
Interventions
DRUG

Docetaxel

6 courses of docetaxel 75 mg/sqm iv

DRUG

Apalutamide Oral Tablet

240 mg /daily orally

DRUG

Enzalutamide Oral Tablet

600 mg /daily orally

DRUG

Abiraterone acetate tablets

1000 mg /daily orally

DRUG

Darolutamide Oral Tablet

600 mg/daily orally

RADIATION

radiotherapy

radical radiotherapy on primary tumor

DRUG

Triptorelin

3,75 mg im/4 w

Trial Locations (3)

10043

RECRUITING

Azienda Ospedaliera San Luigi, Orbassano

35128

RECRUITING

Istituto Oncologico Veneto, Padua

38122

RECRUITING

Santa Chiara Hospital, Trento

All Listed Sponsors
lead

Santa Chiara Hospital

OTHER